Reversing paclitaxel resistance in ovarian cancer cells via inhibition of the abcb1 expressing side population

Tumor Biology

Volumn 35, Issue 10, 2014, Pages 9879-9892

  Eyre, Rachel ^a   Harvey, Ian ^a   Stemke Hale, Katherine ^b   Lennard, Thomas W J ^a   Tyson Capper, Alison ^a   Meeson, Annette P ^a,c  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c INSTITUTE OF HUMAN GENETICS   (United Kingdom)

Author keywords

ABCB1; Ovarian cancer; Paclitaxel; Side population cells

Indexed keywords

ABCB1 PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; MULTIDRUG RESISTANCE PROTEIN; PACLITAXEL;

CANCER STEM CELL; DRUG RESISTANCE; FEMALE; GENE SILENCING; HUMAN; METABOLISM; OVARY TUMOR; PATHOLOGY; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIDE POPULATION CELL; TUMOR CELL LINE; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; BLOTTING, WESTERN; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE KNOCKDOWN TECHNIQUES; HUMANS; NEOPLASTIC STEM CELLS; OVARIAN NEOPLASMS; P-GLYCOPROTEINS; PACLITAXEL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIDE-POPULATION CELLS;

EID: 84922394984     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1007/s13277-014-2277-2     Document Type: Article

References (32)

1. Ponnusamy MP, Batra SK. Ovarian cancer: emerging concept on cancer stem cells. J Ovarian Res. 2008;1(1):4–13.
2. Fallowfield L, Fleissig A, Barrett J, Menon U, Jacobs T, Kilkerr J, et al. Awareness of ovarian cancer risk factors, beliefs and attitudes towards screening: baseline survey of 21 715 women participating in the UK Collaborative Trial of Ovarian Cancer Screening. Br J Cancer. 2010;103:454–61.
3. Vathipadiekal V, Saxena D, Mok SC, Hauschka PV, Ozbun L, Birrer MJ. Identification of a potential ovarian cancer stem cell gene expression profile from advanced stage papillary serous ovarian cancer. PLoS One. 2012;7(1):e29079.
4. Yap TA, Carden CP, Kaye SB. Beyond chemotherapy: targeted therapies in ovarian cancer. Nat Rev Cancer. 2009;9:167–81.
5. Bapat SA. Human ovarian cancer stem cells. Reproduction. 2010;140(1):33–41.
6. Baba T, Convery PA, Matsumura N, Whitaker RS, Kondoh E, Perry T, et al. Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells. Oncogene. 2008;28(2):209–18.
7. Curley MD, Therrien VA, Cummings CL, Sergent PA, Koulouris CR, Friel AM, et al. CD133 expression defines a tumor initiating cell population in primary human ovarian cancer. Stem Cells. 2009;27(12):2875–83.
8. Alvero AB, ChenR,FuHH, Montagna M.Molecular phenotyping of human ovarian cancer stem cells unravel the mechanisms for repair and chemoresistance. Cell Cycle. 2009;8(1):158–66.
9. Zhang Y, Piao, B., Zhang, Y., Hua, B., Hou, W., Xu, W., Qi, X., Zhu, X., Pei, Y., Lin, H. Oxymatrine diminishes the side population and inhibits the expression of β-catenin in MCF-7 breast cancer cells. Med Oncol. 2010.
10. Gao MQ, Choi YP, Kang S, Youn JH, Cho NH. CD24+ cells from hierarchically organized ovarian cancer are enriched in cancer stem cells. Oncogene. 2010;29(18):2672–80.
11. Balicki D. Moving forward in human mammary stem cell biology and breast cancer prognostication using ALDH1. Cell Stem Cell. 2007;1(5):485–7.
12. Hirschmann-Jax C, Foster AE, Wulf GG, Nuchtern JG, Jax TW, Gobel U, et al. A distinct “side population” of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci USA. 2004;101 (39):14228-33.
13. Ho MM, Ng AV, Lam S, Hung JY. Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. Cancer Res. 2007;67(10):4827–33.
14. Chiba T, Kita K, Zheng Y-W, Yokosuka O, Saisho H, Iwama A, et al. Side population purified from hepatocellular carcinoma cells harbors cancer stem cell–like properties. Hepatology. 2006;44(1):240–51.
15. Haraguchi N, Utsunomiya T, Inoue H, Tanaka F, Mimori K, Barnard GF, et al. Characterisation of a side population of cancer cells from human gastrointestinal system. Stem Cells. 2006;24(3):506–13.
16. Moserle L, Indraccolo S, Ghisi M, Frasson C, Fortunato E, Canevari S, et al. The side population of ovarian cancer cells is a primary target of IFN-alpha antitumor effects. Cancer Res. 2008;68(14):5658–68.
17. Hosonuma S, Kobayashi Y, Kojo S, Wada H, Seino K-i, Kiguchi K, et al. Clinical significance of side population in ovarian cancer cells. Hum Cell. 2011;24(1):9–12.
18. Choi YP, Shim HS, Gao M-Q, Kang S, Cho NH. Molecular portraits of intratumoral heterogeneity in human ovarian cancer. Cancer Lett. 2011;307(1):62–71.
19. Hu L, McArthur C, Jaffe RB. Ovarian cancer stem-like side-population cells are tumourigenic and chemoresistant. Br J Cancer. 2010;102(8):1276–83.
20. Rizzo S, Hersey JM, Mellor P, Dai W, Santos-Silva A, Liber D, et al. Ovarian cancer stem cell-like side populations are enriched following chemotherapy and overexpress EZH2. Mol Cancer Ther. 2011;10(2): 325–35.
21. Gao Q, Geng L, Kvalheim G, Gaudernack G, Suo Z. Identification of cancer stem-like side population cells in ovarian cancer cell line OVCAR-3. Ultrastruct Pathol. 2009;33(4):175–81.
22. Dou J, Jiang C, Wang J, Zhang X, Zhao F, Hu W, et al. Using ABCG2-molecule-expressing side population cells to identify cancer stem-like cells in a human ovarian cell line. Cell Biol Int. 2011;35(3): 227–34.
23. Szotek PP, Pieretti-Vanmarcke R, Masiakos PT, Dinulescu DM, Connolly D, Foster R, et al. Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness. Proc Natl Acad Sci U S A. 2006;103(30):11154–9.
24. Golebiewska A, Brons NH, Bjerkvig R, Niclou SP. Critical appraisal of the side population assay in stem cell and cancer stem cell research. Cell Stem Cell. 2011;8(2):136–47.
25. Kobayashi Y, Seino K, Hosonuma S, Ohara T, Itamochi H, Isonishi S, et al. Side population is increased in paclitaxel-resistant ovarian cancer cell lines regardless of resistance to cisplatin. Gynecol Oncol. 2011;121(2):390–4.
26. Tavaluc RT, Hart LS, Dicker DT, El-Deiry WS. Effects of low confluency, serum starvation and hypoxia on the side population of cancer cell lines. Cell Cycle. 2007;6(20):2554–62.
27. Lee JP, Hahn HS, Hwang SJ, Choi JY, Park JS, Lee IH, et al. Selective cyclooxygenase inhibitors increase paclitaxel sensitivity in taxane-resistant ovarian cancer by suppressing P-glycoprotein expression. J Gynecol Oncol. 2013;24(3): 273–9.
28. Zhang J, Zhao J, Zhang W, Liu G, Yin D, Li J, et al. Establishment of paclitaxel-resistant cell line and the underlying mechanism on drug resistance. Int J Gynecol Cancer Off J Int Gynecol Cancer Soc. 2012;22(9):1450–6.
29. Chen J, Wang J, Zhang Y, Chen D, Yang C, Kai C, et al. Observation of ovarian cancer stem cell behavior and investigation of potential mechanisms of drug resistance in three-dimensional cell culture. J Biosci Bioeng. 2014 Mar 27.
30. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer. 2005;5(4):275–84.
31. Johnatty SE, Beesley J, Gao B, Chen X, Lu Y, Law MH, et al. ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: a comprehensive analysis from the Ovarian Cancer Association Consortium and The Cancer Genome Atlas. Gynecol Oncol. 2013;131(1):8–14.
32. Cirak S, Arechavala-Gomeza V, Guglieri M, Feng L, Torelli S, Anthony K, et al. Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study. Lancet. 2011;378(9791):595–605.